title: Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome.
abstract: Neuroleptic Malignant Syndrome (NMS) rarely results from atypical antipsychotic therapy. To date, no information is available on the incidence of NMS with aripiprazole, a newer neuroleptic.
  
  
  OBJECTIVE
  To examine the results of a trial of aripiprazole administered to a 13-year-old Mexican-American girl during the course of NMS.
  
  
  METHODS
  Vital signs and laboratory values obtained before and during the aripiprazole trial were compared.
  
  
  RESULTS
  Aripiprazole administration resulted in a mild increase in tachycardia and brief worsening of serum creatinine kinase level, but did not significantly affect temperature, respiratory rate, or blood pressure.
  
  
  CONCLUSIONS
  In this adolescent with NMS, aripiprazole treatment was associated with a mild worsening of symptoms.
authors.affiliation: Department of Psychiatry, Wake Forest University Baptist Medical Center, Winston-Salem, NC 27157, USA. rdew@wfubmc.edu
authors.forename: Rachel E
authors.initials: RE
authors.lastname: Dew
authors.forename: Peter B
authors.initials: PB
authors.lastname: Rosenquist
authors.forename: W Vaughn
authors.initials: WV
authors.lastname: McCall
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D005260:Female; D006801:Humans; D017058:Mexican Americans; D009459:Neuroleptic Malignant Syndrome / Q000503:physiopathology* / Q000523:psychology; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole